Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28956473 | 1.00 | SMO (0.34) | SMOPYGLPOLBKCNH2APLNR | |
| SCHEMBL12200527 | 1.00 | SMO (0.34) | SMOPYGLPOLBKCNH2APLNR | |
| SCHEMBL20204744 | 0.80 | APLNR (0.35) | POLBAPLNR | |
| SCHEMBL15075617 | 0.79 | APLNR (0.33) | POLBAPLNR | |
| Propylene Glycol SCHEMBL28450622 | 0.78 | TDP1 (0.50) | POLBAPLNR | |
| SCHEMBL19053655 | 0.78 | NPC1 (0.33) | POLBAPLNR | |
| SCHEMBL2702069 | 0.77 | PYGL (0.34) | PYGL | |
| SCHEMBL3297238 | 0.77 | PYGL (0.34) | PYGL | |
| SCHEMBL18245582 | 0.74 | APLNR (0.38) | POLBAPLNR | |
| SCHEMBL8341748 | 0.72 | PYGL (0.32) | PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8034819-B2 | Glucokinase activator | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-11 | — | — | US | disclosed |
| US-8034819-B2 | Glucokinase activator | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20100099671-A1 | GLUCOKINASE ACTIVATOR | TEIJIN LIMITED (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099671-A1 | GLUCOKINASE ACTIVATOR | TEIJIN LIMITED (JP) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | SMO 1481/4885PYGL 692/4885POLB 4747/4885 |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | SMO 1481/4885PYGL 692/4885POLB 4747/4885 |
| US-20100099671-A1 | GLUCOKINASE ACTIVATOR | GCK, GCKR, GALK1 | SMO 3552/4885PYGL 353/4885POLB 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.